Oncological advantage of nonintubated thoracic surgery: Better compliance of adjuvant treatment after lung lobectomy

In this study, we aimed to compare protocol compliance and toxic complications during adjuvant chemotherapy after intubated and nonintubated VATS lobectomies in non‐small cell lung cancer (NSCLC).MethodsWe retrospectively reviewed the medical records of 66, stage IB –IIIB NSCLC patients who underwent intubated or nonintubated VATS lobectomy and received adjuvant chemotherapy.ResultsA total of 38 patients (17 males, mean age 64  years) underwent conventional VATS and 28 (7 males; mean age 63 years) uniportal VATS NITS. Both groups had comparable demographic data, preoperative pulmonary function, and Eastern Cooperative Oncology Group (ECOG) status. Among the intubated and nonintubated patients, 82% and 75% were diagnos ed with adenocarcinoma, respectively. The incidence of adenocarcinoma and squamous cell carcinoma cases were similar in both groups; however, the pathological staging showed significant differences, as 5 (18%) nonintubated patients had stage IB lung cancer, compared with the intubated group (P = 0.01). Further distribution of stages was similar between the groups. We observed significant differences in chest tube duration and operation time in the nonintubated group (P 
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Chenyu Wang, Haixia Li, Yongshun Chen, Hong GeIndian Journal of Cancer 2020 57(3):323-329 Background: The patterns of local failure in stage pN2 nonsmall-cell lung cancer (NSCLC) patients undergoing radical resection and adjuvant chemotherapy are controversial. Methods: The sites of local failure were compared in subgroups of patients with relevant clinicopathologic features (e.g., location and size of primary lesions). Results: Totally 75 patients with local failure after radical resection and adjuvant chemotherapy for pN2 NSCLC were included in the analysis. Thirty-seven (49.3%) patients had distant metastasis. Th...
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
As the leading cause of cancer-related death worldwide, lung cancer still keeps increasing prevalence [1]. Non-small cell lung cancer (NSCLC) has the highest incidence approximately accounting for 85%-90% of all lung cancer cases and could be classified as adenocarcinoma, squamous cell carcinoma and large-cell carcinoma [2]. Over the last decade, significant progress has been achieved in NSCLC and it is certain that tyrosine kinase inhibitors (TKIs) have become the first-line recommendation for patients harboring epidermal growth factor receptor (EGFR) mutations [3,4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer is divided mainly into lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), and large cell carcinoma (LCC) [1]. Although great progress has been made in targeted treatment and immunotherapy, Platinum-based combination chemotherapy is still the standard chemotherapy treatment for wild type lung adenocarcinoma, and cisplatin (DDP) is widely used [2,3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study aimed to investigate the effect of clinical and pathological indicators at the time of diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer. METHODS: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Süleyman Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the Medical Oncology Outpatient Clinic. RESULTS: A total of 518 patients including 260 patients with squamous cell carcinoma, 207 patients with adenocarcinoma, 50 patients with non-small cell lung cancer-not otherwis...
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Background: Serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21-1) and squamous-cell carcinoma-related antigen (SCC-Ag) are routinely used for monitoring the response to chemotherapy or targeted therapy in advanced-stage non-small cell lung cancer (NSCLC), however their role in immunotherapy remains unclear. The aim of this study was to investigate whether dynamics of these serum markers were associated with the efficacy and prognosis of Chinese late-stage NSCLC patients treated with programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors.M...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
CONCLUSION: Infiltration of CD8+ FOXP3+ T cells, CD8+ T cells, and FOXP3+ T cells is important in non-small cell lung cancer microenvironment, and needs to be investigated more. PMID: 32509058 [PubMed]
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Tags: Int J Clin Exp Pathol Source Type: research
Immune checkpoint inhibitors (ICIs) are currently used as monotherapy or combination therapy in frontline and subsequent lines for metastatic lung cancer including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer (SCLC) [1 –5]. Furthermore, ICIs before or after surgery showed efficacy in patients with resectable disease, highlighting the potential of ICIs to improve outcomes in these patients and expand the use of ICIs in the neoadjuvant and adjuvant settings [6,7]. Despite higher response rates, longer duration of response, and less toxicity of ICIs compared with chemotherapy, many lung cancer pat...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionOur findings confirm pericardial effusion as a relatively frequent side effect of immunotherapy in NSCLC. Clinicians should be aware of this specific toxicity in patients with metastatic NSCLC receiving immunotherapy and refer to a cardiologist for a multidisciplinary approach.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Conclusions: The SUVLN on 18F-alfatide PET/CT may be the preferred parameter for predicting the survival of lung cancer.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer (Poster Session) Source Type: research
Conclusion: Among this large cohort, our center seems to follow the global trend with increasing incidence of ADC. EGFR mutation positivity was similar to existing reports, while higher ALK positivity was detected. A characteristic phenotype of never-smokers with lung cancer was elucidated which demonstrated better survival.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
More News: Adenocarcinoma | Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Cardiovascular & Thoracic Surgery | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology